Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases|IX and XII as a unique and novel cancer treatment

• Research unit: INNOSUISSE
• Project number: 14446.1 PFLS-LS

Short description (German)

Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases IX and XII as a unique and novel cancer treatment

Short description (English)

Bi-specific antibody-based molecules for simultaneous targeting of carbonic anhydrases|IX and XII as a unique and novel cancer treatment

Abstract (German)

Tumor cells escape poor oxygenation (hypoxia) by overexpression of Carbonic Anhydrases (CA), in particular CAIX and CAXII, which leads to a growth advantage with|increased metastasis formation and poor patient survival. siRNA targeting of both CA proteins reduces tumor growth in animal models but is hardly applicable in the clinic due to unfavourable in vivo PK/PD properties. As a novel therapeutic approach, we will generate fully human CAIX and CAXII inhibiting antibodies and combine them in a new bi-specific antibody format to target both CAs simultaneously.

Abstract (English)

Tumor cells escape poor oxygenation (hypoxia) by overexpression of Carbonic Anhydrases (CA), in particular CAIX and CAXII, which leads to a growth advantage with|increased metastasis formation and poor patient survival. siRNA targeting of both CA proteins reduces tumor growth in animal models but is hardly applicable in the clinic due to unfavourable in vivo PK/PD properties. As a novel therapeutic approach, we will generate fully human CAIX and CAXII inhibiting antibodies and combine them in a new bi-specific antibody format to target both CAs simultaneously.